Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Safety and Efficacy of Blinatumomab- Real World Data

Arie Apel, MD, Yishai Ofran, MD, Ron Ram, MD, Itai Levi, MD, Miri Zektser, MD, Maya Koren-Michowitz, MD

Blood (2018) 132 (Supplement 1): 5209.

https://doi.org/10.1182/blood-2018-99-116183

Published: 2018

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Tsila Zuckerman, MD, Stela Gengrinovitch, PhD, Ruth Ben-Yakar, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Maya Koren-Michowitz, MD, Shay Yeganeh, MD, Martin S. Tallman, MD, Jacob M. Rowe, MD

Blood (2016) 128 (22): 1650.

https://doi.org/10.1182/blood.V128.22.1650.1650

Published: 2016

Journal Articles

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

Noa Lavi, MD, Maya Koren-Michowitz, MD, Avi Leader, MD, Adi Shacham-Abulafia, MD, Shirley Shapira, MD, Najib Dally, MD, Evgeni Chubar, MD, Elena Mishchenko, MD, Martin H. Ellis, MD

Blood (2015) 126 (23): 4081.

https://doi.org/10.1182/blood.V126.23.4081.4081

Published: 2015

Journal Articles

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

Simon Durrant, MD, Maya Koren-Michowitz, MD, David Lavie, Joaquin Martinez-Lopez, MD PhD, Alessandro M. Vannucchi, MD, Francesco Passamonti, MD, Viktoriya Stalbovskaya, PhD, Edric Atienza, MSHS, Dana Iommazzo, Prashanth Gopalakrishna, MBBS, MRCS, Heinz Gisslinger, MD

Blood (2014) 124 (21): 710.

https://doi.org/10.1182/blood.V124.21.710.710

Published: 2014

Journal Articles

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

Katia Beider, PhD, Evgenia Rosenberg, Hanna Bitner, Merav Leiba, MD, Maya Koren-Michowitz, MD, Michal Abraham, PhD, Shiri Klein, Hanna Wald, Avichai Shimoni, MD, Amnon Peled, PhD, Arnon Nagler, MD

Blood (2014) 124 (21): 4707.

https://doi.org/10.1182/blood.V124.21.4707.4707

Published: 2014

Journal Articles

Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects

Blood (2014) 124 (21): 3163.

https://doi.org/10.1182/blood.V124.21.3163.3163

Published: 2014

Journal Articles

Essential Thrombocythemia Patients with CALR Mutations Have Increased Platelet Activation Markers Compared to JAK2V617F Mutated Patients

Maya Koren-Michowitz, MD, Hagit Hauschner, PhD, Yulia Shuly, MA, Meital Nagar, PhD, Elena Ribakovsky, MD, Mudi Misgav, MD, Odit Gutwein, MD, Uri Seligsohn, MD, Nurit Rosenberg, PhD, Arnon Nagler, MD

Blood (2014) 124 (21): 3223.

https://doi.org/10.1182/blood.V124.21.3223.3223

Published: 2014

Journal Articles

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Martin H. Ellis, MD, Noa Lavi, MD, Elena Mishchenko, MD, Najib Dally, MD, David Lavie, MD, Anna Courevitch, MD, Odit Gutwein, MD, Shlomo Bulvik, MD, Andrei Braester, MD, Evgeni Chubar, MD, Sigal Tavor, MD, Adrian Duek, MD, Ilya Kirgner, MD, Maya Koren-Michowitz, MD

Blood (2014) 124 (21): 1830.

https://doi.org/10.1182/blood.V124.21.1830.1830

Published: 2014

Journal Articles

Adaptor Protein Lnk Binds to and Inhibits Normal and Leukemic FLT3

Dechen Lin, PhD, Tong Yin, MD, PhD, Maya koren-Michowitz, MD, Ling-Wen Ding, Saskia Gueller, MD, Sigal Gery, PhD, Takayuki Tabayashi, MD, Ulla Bergholz, Julhash Kazi, Lars Rönnstrand, PhD, Carol Stocking, Phillip Koeffler, MD

Blood (2012) 120 (21): 1312.

https://doi.org/10.1182/blood.V120.21.1312.1312

Published: 2012

Journal Articles

Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis

Maya koren-Michowitz, MD, Carsten Müller-Tidow, MD, Aiko Matsubara, MS, Stefanie Göllner, PhD, Wolfgang E. Berdel, Arnon Nagler, M.D., Seishi Ogawa, MD, PhD, H. Phillip Koeffler, MD

Blood (2010) 116 (21): 2479.

https://doi.org/10.1182/blood.V116.21.2479.2479

Published: 2010

Journal Articles

Adaptor Protein Lnk Negatively Regulates Bcr-Abl-Induced Cell Proliferation through Inhibition of the Stat5 Signaling Pathway.

Takayuki Tabayashi, MD, Sigal Gery, PhD, Maya Koren-Michowitz, MD, H.Phillip Koeffler, MD

Blood (2010) 116 (21): 3406.

https://doi.org/10.1182/blood.V116.21.3406.3406

Published: 2010

Journal Articles

Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor

Maya koren-Michowitz, MD, Sigal Gery, PhD, Daniel Nowak, MD, Arnon Nagler, M.D., Aiko Matsubara, MS, Takayuki Tabayashi, MD, PhD, Seishi Ogawa, MD, PhD, H. Phillip Koeffler, MD

Blood (2010) 116 (21): 2785.

https://doi.org/10.1182/blood.V116.21.2785.2785

Published: 2010

Journal Articles

Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.

Maya Koren-Michowitz, MD, Philipp D. le Coutre, MD, Justus Duyster, MD, Christof Scheid, Panayiotis Panayiotidis, Witold Prejzner, MD, Jacob M. Rowe, MD, Michaela Schwarz, Neta Goldschmidt, MD, Arnon Nagler, MD

Blood (2009) 114 (22): 3297.

https://doi.org/10.1182/blood.V114.22.3297.3297

Published: 2009

Journal Articles

Adaptor Protein Lnk Binds to JAK3 and Negatively Regulates a Mutant Activating Allele Associated with Megakaryocytic Leukemia.

Maya Koren-Michowitz, MD, Sigal Gery, PhD, Daniel Nowak, MD, Phillip H Koeffler, MD

Blood (2009) 114 (22): 5044.

https://doi.org/10.1182/blood.V114.22.5044.5044

Published: 2009

Journal Articles

Transformation to Myelofibrosis and Blastic Transformation of PV Are Associated with Higher JAK2 Mutation Levels.

Maya Koren-Michowitz, MD, Ninette Amariglio, PhD, Joseph Landman, BA, Gideon Rechavi, MD, PhD, Elena Ribakovsky, MD, Yoram Cohen, MD, Arnon Nagler, MD, MSc

Blood (2007) 110 (11): 1555.

https://doi.org/10.1182/blood.V110.11.1555.1555

Published: 2007

Journal Articles

Near-Tetraploidy Can Mask the Presence of Chromosome 13q Deletions in Plasma Cells of Patients with Multiple Myeloma.

Maya Koren-Michowitz, MD, Izhar Hardan, MD, Janina Berghoff, MA, Galina Yshoev, MD, Ninette Amariglio, PhD, Gideon Rechavi, MD PhD, Arnon Nagler, MD, MSc, Luba Trakhtenbrot, PhD

Blood (2006) 108 (11): 4280.

https://doi.org/10.1182/blood.V108.11.4280.4280

Published: 2006

Journal Articles

Towards Stopping Imatinib Therapy under the Umbrella of Interferone: Alpha-Interferone Improves Molecular Response in CML Patients with Imatinib Induced Complete Cytogenetic Remission: An Early Observation from a Study of Pegylated Interferone in the Set up of Minimal Residual Disease.

Izhar Hardan, MD, Ninette Amariglio, PhD, Luba Trakhtenbrot, PhD, Avichai Shimoni, MD, Maya Koren-Michowitz, MD, Gideon Rechavi, MD PhD, Arnon Nagler, MD

Blood (2006) 108 (11): 4788.

https://doi.org/10.1182/blood.V108.11.4788.4788

Published: 2006

NARROW

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Safety and Efficacy of Blinatumomab- Real World Data

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Anticoagulation Therapy for Venous Thrombotic Events in Patients with Myeloproliferative Neoplasms

HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects

Essential Thrombocythemia Patients with CALR Mutations Have Increased Platelet Activation Markers Compared to JAK2V617F Mutated Patients

Ruxolitinib Treatment for Myelofibrosis: Efficacy and Tolerability in a Real-World Setting

Adaptor Protein Lnk Binds to and Inhibits Normal and Leukemic FLT3

Older Patients with Normal Cytogenetics AML Have a Higher Rate of Genomic Changes Compared to Young Patients as Determined by SNP Chip Analysis

Adaptor Protein Lnk Negatively Regulates Bcr-Abl-Induced Cell Proliferation through Inhibition of the Stat5 Signaling Pathway.

Adaptor Protein LNK Binds to and Is Phosphorylated by JAK3 and May Serve as a Scaffold for JAK3 Autophosphorylation In the Absence of An Appropriate Cytokine Receptor

Prior Response to Imatinib Predicts Response to Second Line Treatment with Nilotinib in CML Patients Resistant or Intolerant to Imatinib.

Adaptor Protein Lnk Binds to JAK3 and Negatively Regulates a Mutant Activating Allele Associated with Megakaryocytic Leukemia.

Transformation to Myelofibrosis and Blastic Transformation of PV Are Associated with Higher JAK2 Mutation Levels.

Near-Tetraploidy Can Mask the Presence of Chromosome 13q Deletions in Plasma Cells of Patients with Multiple Myeloma.

Towards Stopping Imatinib Therapy under the Umbrella of Interferone: Alpha-Interferone Improves Molecular Response in CML Patients with Imatinib Induced Complete Cytogenetic Remission: An Early Observation from a Study of Pegylated Interferone in the Set up of Minimal Residual Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only